Venus Remedies Limited (BOM:526953)
1,221.80
+58.15 (5.00%)
At close: May 27, 2026
Venus Remedies Employees
Venus Remedies had 1,298 employees as of March 31, 2025. The number of employees increased by 111 or 9.35% compared to the previous year.
Employees
1,298
Change (1Y)
111
Growth (1Y)
9.35%
Revenue / Employee
6.03M INR
Profits / Employee
791.83K INR
Market Cap
15.55B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 1,298 | 111 | 9.35% |
| Mar 31, 2024 | 1,187 | 189 | 18.94% |
| Mar 31, 2023 | 998 | 56 | 5.94% |
| Mar 31, 2022 | 942 | 105 | 12.54% |
| Mar 31, 2021 | 837 | -72 | -7.92% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lincoln Pharmaceuticals | 1,853 |
| Morepen Laboratories | 1,814 |
| Wanbury | 1,382 |
| TTK Healthcare | 1,339 |
| Kwality Pharmaceuticals | 997 |
| Syncom Formulations (India) | 744 |
| Amrutanjan Health Care | 737 |
| Fermenta Biotech | 606 |
Venus Remedies News
- 1 day ago - Venus Remedies announces ₹10 per share final dividend with record date set for August 2026 - Business Upturn
- 1 day ago - Venus Remedies schedules AGM for August 2026 and announces dividend - Business Upturn
- 5 days ago - Venus Remedies shares rally 4% after Saudi Arabia approves oncology drug Plerixafor for global marketing authorization - Business Upturn
- 5 days ago - Venus Remedies receives Saudi FDA approval for Plerixafor - Business Upturn
- 6 days ago - Venus Remedies promotes KYC awareness through social media - Business Upturn
- 1 year ago - Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility - Business Upturn
- 1 year ago - Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034 - Business Upturn
- 1 year ago - Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034 - Business Upturn